Keyvan Shabafrouz

2.2k total citations · 1 hit paper
6 papers, 1.6k citations indexed

About

Keyvan Shabafrouz is a scholar working on Oncology, Pathology and Forensic Medicine and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Keyvan Shabafrouz has authored 6 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Oncology, 1 paper in Pathology and Forensic Medicine and 1 paper in Pulmonary and Respiratory Medicine. Recurrent topics in Keyvan Shabafrouz's work include Cancer Immunotherapy and Biomarkers (5 papers), Colorectal Cancer Treatments and Studies (2 papers) and Cancer Research and Treatments (1 paper). Keyvan Shabafrouz is often cited by papers focused on Cancer Immunotherapy and Biomarkers (5 papers), Colorectal Cancer Treatments and Studies (2 papers) and Cancer Research and Treatments (1 paper). Keyvan Shabafrouz collaborates with scholars based in Switzerland, France and United States. Keyvan Shabafrouz's co-authors include Michel Obéid, Yan Guex‐Crosier, Camillo Ribi, Gerasimos P. Sykiotis, Faïza Lamine, Montserrat Fraga, Thierry Küntzer, Olivier Michielin, François Spertini and Filipe Martins and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Oncology and Nature Reviews Clinical Oncology.

In The Last Decade

Keyvan Shabafrouz

6 papers receiving 1.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance

2019 1.5k citations Filipe Martins, Sofiya Latifyan et al. Nature Reviews Clinical Oncology profile →

Peers

Keyvan Shabafrouz

ONCOL

IMMUN

PRM

MB

EPIDE

Filipe Martins Switzerland

Sofiya Latifyan Switzerland

Anne Cairoli Switzerland

C. Boutros France

Matthieu Texier France

Niamh M. Keegan United States

Alejandra Flores-Chávez Spain

Ulf Petrausch Switzerland

Katja Schindler United States

Louise C. Connell United States

Filipe Martins Switzerland

Keyvan Shabafrouz

1.4k ×1.1

ONCOL

510 ×1.1

IMMUN

403 ×1.2

PRM

258 ×1.1

MB

145 ×1.2

EPIDE

Citations per year, relative to Keyvan Shabafrouz Keyvan Shabafrouz (= 1×) peers Filipe Martins

Countries citing papers authored by Keyvan Shabafrouz

Since Specialization

Citations

This map shows the geographic impact of Keyvan Shabafrouz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Keyvan Shabafrouz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Keyvan Shabafrouz more than expected).

Fields of papers citing papers by Keyvan Shabafrouz

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Keyvan Shabafrouz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Keyvan Shabafrouz. The network helps show where Keyvan Shabafrouz may publish in the future.

Co-authorship network of co-authors of Keyvan Shabafrouz

This figure shows the co-authorship network connecting the top 25 collaborators of Keyvan Shabafrouz. A scholar is included among the top collaborators of Keyvan Shabafrouz based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Keyvan Shabafrouz. Keyvan Shabafrouz is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

6 of 6 papers shown

1.

Daoudlarian, Douglas, et al.. (2024). Tocilizumab provides dual benefits in treating immune checkpoint inhibitor-associated arthritis and preventing relapse during ICI rechallenge: the TAPIR study. Annals of Oncology. 36(1). 43–53. 10 indexed citations

2.

Obéid, Michel, Victor Joo, Douglas Daoudlarian, et al.. (2024). High-dimensional longitudinal immune profiling uncovers a dual role of the CXCL9/CXCR3, CXCL13/CXCR5, and CCL11/CCL3 axis in the coupling of immune-related adverse events to immune checkpoint inhibitor response.. Journal of Clinical Oncology. 42(16_suppl). 2512–2512. 1 indexed citations

3.

Martins, Filipe, Sofiya Latifyan, Gerasimos P. Sykiotis, et al.. (2019). Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance. Nature Reviews Clinical Oncology. 16(9). 563–580. 1544 indexed citations breakdown →

4.

Deplanque, G., Keyvan Shabafrouz, & Michel Obéid. (2017). Can local radiotherapy and IL-12 synergise to overcome the immunosuppressive tumor microenvironment and allow “in situ tumor vaccination”?. Cancer Immunology Immunotherapy. 66(7). 833–840. 20 indexed citations

5.

Monnier, Yan, et al.. (2017). [Head and neck cancer : promising results of immunotherapy].. PubMed. 13(563). 1029–1031. 1 indexed citations

6.

Shabafrouz, Keyvan, Jean Bauer, & Dominik Berthold. (2010). [New drugs at the horizon for men with prostate cancer].. PubMed. 6(250). 1057–8, 1060. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact